FREEHOLD, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that ...
By application, neuropathic pain is expected to lead the market ... and this expansion can be attributed to R&D investments in the development of technologically advanced healthcare treatment options.
(NASDAQ: AMIX) ("Autonomix” or the "Company”), a medical device company focused on advancing precision nerve-targeted treatments, today highlighted positive preliminary results from the first five ...
Medically reviewed by Jay N. Yepuri, MD Medically reviewed by Jay N. Yepuri, MD Crohn's disease flare-ups can occur due to internal or external triggers, which vary by person. Knowing your triggers ...